ATE383375T1 - Wti-modifiziertes peptid - Google Patents

Wti-modifiziertes peptid

Info

Publication number: ATE383375T1
Authority: AT; Austria
Prior art keywords: wti; modified peptide; active ingredient; peptide; dna
Prior art date: 2001-03-22

Application number

AT02708646T

Other languages

English (en)

Inventor

Haruo Sugiyama

Original Assignee

Int Inst Cancer Immunology Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-22

Filing date

2002-03-22

Publication date

2008-01-15

2002-03-22 Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc

2008-01-15 Application granted granted Critical

2008-01-15 Publication of ATE383375T1 publication Critical patent/ATE383375T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
239000004480 active ingredient Substances 0.000 abstract 2
VXDXZGYXHIADHF-YJRXYDGGSA-N Cys-Tyr-Thr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VXDXZGYXHIADHF-YJRXYDGGSA-N 0.000 abstract 1
108010041986 DNA Vaccines Proteins 0.000 abstract 1
229940021995 DNA vaccine Drugs 0.000 abstract 1
YNOVBMBQSQTLFM-DCAQKATOSA-N Met-Asn-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O YNOVBMBQSQTLFM-DCAQKATOSA-N 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
NAQBQJOGGYGCOT-QEJZJMRPSA-N Trp-Asn-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O NAQBQJOGGYGCOT-QEJZJMRPSA-N 0.000 abstract 1
150000001413 amino acids Chemical group 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
229940022399 cancer vaccine Drugs 0.000 abstract 1
238000009566 cancer vaccine Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Zoology (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)

AT02708646T 2001-03-22 2002-03-22 Wti-modifiziertes peptid ATE383375T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2001083250		2001-03-22

Publications (1)

Publication Number	Publication Date
ATE383375T1 true ATE383375T1 (de)	2008-01-15

Family

ID=18939092

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02708646T ATE383375T1 (de)	2001-03-22	2002-03-22	Wti-modifiziertes peptid

Country Status (12)

Country	Link
US (2)	US20040097703A1 (de)
EP (1)	EP1371664B1 (de)
JP (2)	JP3728439B2 (de)
KR (1)	KR100863853B1 (de)
CN (1)	CN1281625C (de)
AT (1)	ATE383375T1 (de)
BR (1)	BRPI0208183B8 (de)
CA (1)	CA2440303C (de)
DE (1)	DE60224508T2 (de)
ES (1)	ES2298353T3 (de)
TW (1)	TWI318630B (de)
WO (1)	WO2002079253A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HK1038929B (zh)	1998-07-31	2005-05-06	株式会社国际癌症免疫研究所	基於癌抑制基因wt1的产物的癌抗原
EP1371664B1 (de)	2001-03-22	2008-01-09	International Institute of Cancer Immunology, Inc.	Wti-modifiziertes peptid
US8735357B2 (en) *	2001-09-28	2014-05-27	International Institute Of Cancer Immunology, Inc.	Method of inducing antigen-specific T cells
US20050002951A1 (en) *	2001-09-28	2005-01-06	Haruo Sugiyama	Novel method of inducing antigen-specific t cells
JP2003243616A (ja)	2002-02-20	2003-08-29	Seiko Epson Corp	半導体装置の製造方法
WO2003106682A1 (ja) *	2002-06-12	2003-12-24	中外製薬株式会社	Ｈｌａ−ａ２４拘束性癌抗原ペプチド
AU2003262094A1 (en) *	2002-09-12	2004-04-30	Haruo Sugiyama	Cancer antigen peptide preparation
EP1548028B1 (de)	2002-09-20	2009-09-09	International Institute of Cancer Immunology, Inc.	Substituierte wt1-peptide
KR101399678B1 (ko) *	2003-01-15	2014-05-27	추가이 세이야쿠 가부시키가이샤	이량체화 펩티드
CA2530184C (en)	2003-06-27	2015-10-06	Haruo Sugiyama	Method of selecting patients suitable for wt1 vaccine
US20080070835A1 (en)	2003-11-05	2008-03-20	International Institute Of Cancer Immunology, Inc	Hla-Dr-Binding Antigen Peptide Derived From Wt1
JP4886507B2 (ja) *	2004-03-31	2012-02-29	株式会社癌免疫研究所	Ｗｔ１由来の癌抗原ペプチド
CA2626238C (en)	2005-10-17	2015-10-06	Memorial Sloan Kettering Cancer Center	Wt1 hla class ii-binding peptides and compositions and methods comprising same
ES2352855T3 (es)	2005-11-30	2011-02-23	International Institute Of Cancer Immunology, Inc.	Nuevos compuestos peptídicos del tumor de wilms.
CN102250211A (zh) *	2006-02-22	2011-11-23	株式会社癌免疫研究所	Hla-a*3303限制性wt1肽和包含此肽的药物组合物
US9265816B2 (en)	2006-04-10	2016-02-23	Sloan Kettering Institute For Cancer Research	Immunogenic WT-1 peptides and methods of use thereof
CA2886621A1 (en) *	2006-12-28	2008-07-10	International Institute Of Cancer Immunology, Inc.	Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
PL2119778T3 (pl)	2007-02-27	2016-04-29	Int Inst Cancer Immunology Inc	Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie
US10093977B2 (en)	2007-03-05	2018-10-09	International Institute Of Cancer Immunology, Inc.	Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
JP5478260B2 (ja)	2007-12-05	2014-04-23	株式会社癌免疫研究所	癌ワクチン組成物
NZ609460A (en)	2010-10-05	2015-07-31	Otsuka Pharma Co Ltd	Method for activating helper t cell
KR20140039318A (ko)	2011-06-28	2014-04-01	인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드	펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자
US9539299B2 (en) *	2011-10-27	2017-01-10	International Institute Of Cancer Immunology, Inc.	Combination therapy with WT1 peptide vaccine and temozolomide
CA2861206C (en)	2012-01-13	2021-07-06	Richard J. O'reilly	Immunogenic wt-1 peptides and methods of use thereof
ES2655031T3 (es)	2012-07-02	2018-02-16	Sumitomo Dainippon Pharma Co., Ltd.	Preparación transdérmica de péptido antigénico del cáncer
CA2884366A1 (en)	2012-09-12	2014-03-20	International Institute Of Cancer Immunology, Inc.	Antigen-specific helper t-cell receptor genes
EA201591168A1 (ru)	2012-12-17	2016-05-31	Оцука Фармасьютикал Ко., Лтд.	Способ активации хелперной t-клетки
US10815273B2 (en)	2013-01-15	2020-10-27	Memorial Sloan Kettering Cancer Center	Immunogenic WT-1 peptides and methods of use thereof
CN110078813B (zh) *	2013-01-15	2023-03-28	纪念斯隆凯特林癌症中心	免疫原性wt-1肽和其使用方法
JP6250288B2 (ja) *	2013-01-30	2017-12-20	株式会社医学生物学研究所	Ｔ細胞レセプターおよびその利用
EP2762152A1 (de)	2013-02-05	2014-08-06	Nitto Denko Corporation	WT1-Peptidkrebsimpfstoffzusammensetzung zur transdermalen Verabreichung
IN2014CH00391A (de)	2013-02-05	2015-04-03	Nitto Denko Corp
RU2697443C2 (ru)	2013-02-05	2019-08-14	Нитто Денко Корпорейшн	Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения
KR102045029B1 (ko)	2013-02-05	2019-11-14	닛토덴코 가부시키가이샤	점막 투여용 ｗｔ1 펩티드 암 백신 조성물
JP6294868B2 (ja)	2013-03-12	2018-03-14	大日本住友製薬株式会社	液体水性組成物
EP2982681B8 (de) *	2013-03-29	2018-11-07	Sumitomo Dainippon Pharma Co., Ltd.	Wt1-antigen-peptid-konjugat-vakzin
EP2980097A4 (de)	2013-03-29	2017-03-08	Sumitomo Dainippon Pharma Co., Ltd.	Konjugatimpfstoff mit trimmfunktion von erap1
CA2912514A1 (en)	2013-05-13	2014-11-20	International Institute Of Cancer Immunology, Inc.	Method for predicting clinical effect of immunotherapy
US10253075B2 (en)	2014-02-26	2019-04-09	tella, Inc.	WT1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
ES2916834T3 (es)	2014-09-27	2022-07-06	Sumitomo Pharma Co Ltd	Composición farmacéutica para inyección
US12383608B2 (en)	2016-11-30	2025-08-12	Sumitomo Pharma Co., Ltd.	WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
EP3604325A4 (de)	2017-03-30	2021-01-13	Sumitomo Dainippon Pharma Co., Ltd.	Wt1-krebs-antigen-peptid und peptid-konjugat-körper damit
KR20210068060A (ko)	2018-09-28	2021-06-08	다이니뽄 스미토모 세이야쿠 가부시키가이샤	주사용 조성물
WO2020071551A1 (ja)	2018-10-05	2020-04-09	株式会社癌免疫研究所	良性腫瘍の予防または治療薬
TWI875736B (zh)	2019-02-28	2025-03-11	日商住友製藥股份有限公司	選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
MX2022014249A (es)	2020-05-12	2023-02-22	Sumitomo Pharma Co Ltd	Composición farmacéutica para tratar el cáncer.
CN111647066B (zh) *	2020-07-01	2020-12-18	维肽瀛(上海)生物技术有限公司	Wt1多肽肿瘤抑制剂
CN118076382A (zh)	2021-08-12	2024-05-24	株式会社癌免疫研究所	用于治疗或预防癌症的药用组合物和方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6122018A (ja)	1984-07-06	1986-01-30	Green Cross Corp:The	癌免疫療法増強剤
WO1991007509A1 (en)	1989-11-13	1991-05-30	Massachusetts Institute Of Technology	Localization and characterization of the wilms's tumor gene
JPH09506866A (ja)	1993-12-14	1997-07-08	ジョーンズホプキンスユニバーシティースクールオブメディシン	医薬として活性のある物質の免疫療法のための放出制御
US5622835A (en)	1994-04-28	1997-04-22	The Wistar Institute Of Anatomy & Biology	WT1 monoclonal antibodies
WO1996002555A1 (en)	1994-07-15	1996-02-01	The University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
ES2268705T3 (es) *	1995-06-01	2007-03-16	Kishimoto, Tadamitsu	Inhibidor del crecimiento de celulas leucemicas que contienen un derivado oligonucleotidico antisentido frente al gen del tumor de wiloms (wt1).
JP3904260B2 (ja)	1995-06-01	2007-04-11	岸本忠三	ウイルムス腫瘍遺伝子（ｗｔ１）に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤
PT1435205E (pt) *	1995-09-19	2010-02-04	Bayer Bioscience Gmbh	Plantas que sintetizam um amido modificado, processo para a sua produção e amido modificado
US20030092656A1 (en) *	1997-07-16	2003-05-15	Haruo Sugiyama	Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
JP4789095B2 (ja)	1997-07-16	2011-10-05	治夫杉山	ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤
US5985264A (en)	1998-03-05	1999-11-16	The Medical College Of Ohio	IL-12 Stimulation of Neonatal immunity
HK1038929B (zh)	1998-07-31	2005-05-06	株式会社国际癌症免疫研究所	基於癌抑制基因wt1的产物的癌抗原
US7901693B2 (en) *	1998-09-30	2011-03-08	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) *	1998-09-30	2003-04-17	Alexander Gaiger	Compositions and methods for WT1 specific immunotherapy
PL201881B1 (pl) *	1998-09-30	2009-05-29	Corixa Corp	Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
US7144581B2 (en) *	2000-10-09	2006-12-05	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) *	1998-09-30	2010-02-02	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US20030215458A1 (en) *	1998-09-30	2003-11-20	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) *	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) *	1998-09-30	2003-02-27	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en)	1998-11-02	1998-12-30	Imp College Innovations Ltd	Immunotherapeutic methods and molecules
JP2002534438A (ja)	1999-01-12	2002-10-15	スミスクラインビーチャムバイオロジカルズソシエテアノニム	新規治療法
EP1031346B1 (de)	1999-01-27	2002-05-02	Idea Ag	Nichtinvasive Impfung durch die Haut
EP1074267B1 (de)	1999-07-22	2006-03-15	Dainippon Sumitomo Pharma Co., Ltd.	Induktion von antigen-spezifischen T-Zellen durch Interferon
JP2001089389A (ja)	1999-07-22	2001-04-03	Sumitomo Pharmaceut Co Ltd	抗原特異的ｔ細胞の誘導剤
CA2401070A1 (en)	2000-02-22	2001-08-30	Corixa Corporation	Compositions and methods for diagnosis and therapy of malignant mesothelioma
EP1371664B1 (de)	2001-03-22	2008-01-09	International Institute of Cancer Immunology, Inc.	Wti-modifiziertes peptid
US7553494B2 (en) *	2001-08-24	2009-06-30	Corixa Corporation	WT1 fusion proteins
US8735357B2 (en) *	2001-09-28	2014-05-27	International Institute Of Cancer Immunology, Inc.	Method of inducing antigen-specific T cells
US20050002951A1 (en) *	2001-09-28	2005-01-06	Haruo Sugiyama	Novel method of inducing antigen-specific t cells
WO2003106682A1 (ja)	2002-06-12	2003-12-24	中外製薬株式会社	Ｈｌａ−ａ２４拘束性癌抗原ペプチド
AU2003262094A1 (en)	2002-09-12	2004-04-30	Haruo Sugiyama	Cancer antigen peptide preparation
EP1548028B1 (de)	2002-09-20	2009-09-09	International Institute of Cancer Immunology, Inc.	Substituierte wt1-peptide
KR101399678B1 (ko)	2003-01-15	2014-05-27	추가이 세이야쿠 가부시키가이샤	이량체화 펩티드
CA2530184C (en)	2003-06-27	2015-10-06	Haruo Sugiyama	Method of selecting patients suitable for wt1 vaccine
US20080070835A1 (en)	2003-11-05	2008-03-20	International Institute Of Cancer Immunology, Inc	Hla-Dr-Binding Antigen Peptide Derived From Wt1
JP4886507B2 (ja)	2004-03-31	2012-02-29	株式会社癌免疫研究所	Ｗｔ１由来の癌抗原ペプチド

2002
- 2002-03-22 EP EP02708646A patent/EP1371664B1/de not_active Expired - Lifetime
- 2002-03-22 CA CA2440303A patent/CA2440303C/en not_active Expired - Lifetime
- 2002-03-22 KR KR1020037011790A patent/KR100863853B1/ko not_active Expired - Lifetime
- 2002-03-22 ES ES02708646T patent/ES2298353T3/es not_active Expired - Lifetime
- 2002-03-22 JP JP2002577877A patent/JP3728439B2/ja not_active Expired - Lifetime
- 2002-03-22 TW TW091105633A patent/TWI318630B/zh not_active IP Right Cessation
- 2002-03-22 DE DE60224508T patent/DE60224508T2/de not_active Expired - Lifetime
- 2002-03-22 AT AT02708646T patent/ATE383375T1/de not_active IP Right Cessation
- 2002-03-22 CN CNB028070259A patent/CN1281625C/zh not_active Expired - Lifetime
- 2002-03-22 US US10/471,835 patent/US20040097703A1/en not_active Abandoned
- 2002-03-22 BR BR0208183-0 patent/BRPI0208183B8/pt not_active IP Right Cessation
- 2002-03-22 WO PCT/JP2002/002794 patent/WO2002079253A1/ja not_active Ceased
2005
- 2005-08-08 JP JP2005229180A patent/JP3819930B2/ja not_active Expired - Lifetime
2009
- 2009-09-02 US US12/552,660 patent/US8105604B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1531553A (zh)	2004-09-22
US20040097703A1 (en)	2004-05-20
EP1371664B1 (de)	2008-01-09
DE60224508T2 (de)	2008-12-24
ES2298353T3 (es)	2008-05-16
DE60224508D1 (de)	2008-02-21
CA2440303C (en)	2013-03-19
JP3728439B2 (ja)	2005-12-21
KR100863853B1 (ko)	2008-10-15
JPWO2002079253A1 (ja)	2004-07-22
WO2002079253A1 (en)	2002-10-10
HK1070078A1 (en)	2005-06-10
US8105604B2 (en)	2012-01-31
BRPI0208183B1 (pt)	2018-08-28
CA2440303A1 (en)	2002-10-10
KR20030084970A (ko)	2003-11-01
JP3819930B2 (ja)	2006-09-13
BR0208183A (pt)	2004-03-02
CN1281625C (zh)	2006-10-25
EP1371664A1 (de)	2003-12-17
JP2006034296A (ja)	2006-02-09
BRPI0208183B8 (pt)	2021-05-25
TWI318630B (en)	2009-12-21
EP1371664A4 (de)	2006-03-22
US20090325886A1 (en)	2009-12-31

Legal Events

Date	Code	Title	Description
2008-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60224508D1 (de)	2008-02-21	Wti-modifiziertes peptid
MXPA04000597A (es)	2004-04-20	Peptidos novedosos de la proteina g del virus sincicial respiratorio (rsv), y su uso en una vacuna.
AU2002302255A1 (en)	2002-12-09	Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
DE60235761D1 (de)	2010-05-06	Isoform des vegfs
NO992102L (no)	2000-10-31	Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
NO20073914L (no)	2004-03-10	Biologisk aktive peptider
WO2002059143A3 (en)	2004-01-22	Therapeutic peptides for demyelinating conditions
IS2670B (is)	2010-09-15	Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun
MXPA03010684A (es)	2005-11-04	Peptidos y el uso de los mismos para oscurecer la piel.
BR0214363A (pt)	2004-10-26	Anticorpo, uso de um anticorpo, medicamento, método de fabricação de um medicamento e pacote farmacêutico para o tratamento de infecção
NO20025064L (no)	2002-12-20	RGO koblet til peptider
DE50206480D1 (de)	2006-05-24	Antimikrobiell wirkendes peptid
ATE469655T1 (de)	2010-06-15	Bakteriophagenvermittelte impfung
WO2002058725A3 (fr)	2003-01-09	Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
DE602004028266D1 (de)	2010-09-02	Angiogene peptide und ihre verwendungen
CY1109946T1 (el)	2014-09-10	Τροποποιημενα πεπτιδια και η χρηση τους για τη θεραπεια αυτοανοσων νοσων
DK1268522T3 (da)	2009-01-12	LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
AU2003264535A1 (en)	2004-04-19	Tumor antigen protein and utilization thereof
NZ513549A (en)	2003-03-28	Malaria vaccine
WO2003093300A3 (en)	2004-09-10	Anti-microbial peptides and compositions
ES2176363T3 (es)	2002-12-01	Peptidos de la proteina gag del vih, su preparacion y su uso.
WO2001090139A3 (en)	2002-06-20	A ligand for enhancing oral and cns delivery of biological agents
WO2004000870A3 (en)	2004-08-05	Two synthetic peptides for treatment and prevention of cancers
FR2819256B1 (fr)	2004-04-30	Polypeptide induisant des anticorps neutralisant le vih
IT1307333B1 (it)	2001-10-30	Peptidi derivati dall'allergene parj2 del polline di parietariajudaica.